WO2026133354 - A STABLE ORAL PHARMACEUTICAL COMPOSITION OF FERROUS FUMARATE
National phase entry is expected:
Publication Number
WO/2026/133354
Publication Date
25.06.2026
International Application No.
PCT/IN2025/052062
International Filing Date
15.12.2025
Title **
[English]
A STABLE ORAL PHARMACEUTICAL COMPOSITION OF FERROUS FUMARATE
[French]
COMPOSITION PHARMACEUTIQUE ORALE STABLE DE FUMARATE FERREUX
Applicants **
WOCKHARDT LIMITED
Inventors
SEETHARAMAN, Sritharan
MHASE, Sunil
SHAIKH, Imran G
JAJJAR, Rajeshkumar
Priority Data
202421101000
19.12.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1969 | |
| EPO | Filing, Examination, Granting | 11440 | |
| Japan | Filing, Examination, Granting | 2025 | |
| South Korea | Filing, Examination, Granting | 1781 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,955
Contact Us
Abstract[English]
A stable Ferrous Fumarate pharmaceutical composition in the form of orally administrable tablet comprising 84% w/w ferrous fumarate, 2% w/w gelatin, 11.80 % w/w maize starch, 1.2% w/w liquid paraffin, and 1 % Sodium lauryl sulphate. A process for the preparation of said orally administrable tablet is also disclosed.[French]
Une composition pharmaceutique stable de fumarate ferreux sous forme de comprimé administrable par voie orale, comprenant 84 % p/p de fumarate ferreux, 2 % p/p de gélatine, 11,80 % p/p d'amidon de maïs, 1,2 % p/p de paraffine liquide et 1 % de laurylsulfate de sodium. Un procédé de préparation dudit comprimé administrable par voie orale est également divulgué.